AI assistant
IDEXX LABORATORIES INC /DE — Director's Dealing 2025
Feb 18, 2025
30016_dirs_2025-02-18_1ac03670-53db-4845-bb81-d4409626bbf3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2025-02-13
Reporting Person: Erickson Michael G (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-14 | Common Stock | M | 69 | — | Acquired | 20905.3617 | Direct |
| 2025-02-14 | Common Stock | M | 93 | — | Acquired | 20998.3617 | Direct |
| 2025-02-14 | Common Stock | M | 94 | — | Acquired | 21092.3617 | Direct |
| 2025-02-14 | Common Stock | M | 301 | — | Acquired | 21393.3617 | Direct |
| 2025-02-14 | Common Stock | F | 177 | $444.53 | Disposed | 21216.3617 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-13 | Non-Qualified Stock Option (right-to-buy) | $459.76 | A | 6320 | Acquired | 2035-02-12 | Common Stock (6320) | Direct |
| 2025-02-13 | Incentive Stock Option (right-to-buy) | $459.76 | A | 217 | Acquired | 2035-02-12 | Common Stock (217) | Direct |
| 2025-02-13 | Restricted Stock Unit | $ | A | 734 | Acquired | Common Stock (734) | Direct | |
| 2025-02-13 | Restricted Stock Unit | $ | A | 734 | Acquired | Common Stock (734) | Direct | |
| 2025-02-14 | Restricted Stock Unit | $ | M | 69 | Disposed | Common Stock (69) | Direct | |
| 2025-02-14 | Restricted Stock Unit | $ | M | 93 | Disposed | Common Stock (93) | Direct | |
| 2025-02-14 | Restricted Stock Unit | $ | M | 94 | Disposed | Common Stock (94) | Direct | |
| 2025-02-14 | Restricted Stock Unit | $ | M | 301 | Disposed | Common Stock (301) | Direct |
Footnotes
F1: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026.
F2: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029.
F3: Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026.
F4: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026.
F5: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning on February 14, 2022.
F6: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023.
F7: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2024.
F8: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments, beginning on February 14, 2025.